Form 4: Y-mAbs Therapeutics Executive Sells Shares to Cover Tax Obligations

Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, sold 3,900 shares of common stock on March 5, 2024, to cover tax liabilities associated with vested restricted stock units.

Summary

• Thomas Gad, the Chief Business Officer of Y-mAbs Therapeutics, sold 3,900 shares of the company's common stock on March 5, 2024.
• The sale was executed at a weighted average price of $16.44 per share, with individual trades ranging from $16.41 to $16.52.
• The transaction was a non-discretionary sale to cover tax liabilities related to the vesting and settlement of restricted stock units.
• Following the transaction, Gad directly owns 158,700 shares of Y-mAbs Therapeutics.
• Gad also indirectly owns 265,032 shares through GAD Enterprises LLC and 60,000 shares through his children.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations and doesn't inherently indicate a positive or negative outlook on the company.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning or tax obligations. The sale itself doesn't necessarily indicate a negative outlook on the company's future, but the market may react depending on the size and frequency of such transactions.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units, which vest over time.
• Sales to cover tax obligations upon vesting are a standard practice.
• Comparing the size of this transaction to Gad's overall holdings and to similar transactions by executives at comparable biotech companies would provide further context.

Stakeholder Impact

• The sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although the effect is likely to be minimal given the size of the transaction.

Key Dates